Please assess the completion status of the following clinical trial:

Trial Title: Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females who are greater than or equal to 21 years of age,~* Subjects with a ASCUS (Atypical Squamous Cells - Undetermined Significance) cytology result,~* Females who provide informed consent~Exclusion Criteria:~* Known pregnant~* Prior complete or partial hysterectomy involving removal of cervix~* Conization, LEEP, cervical laser surgery or cryosurgery on the cervix has been performed in the last twelve months~* Colposcopy clinic referral patients

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BD HPV assay on Viper LT (Type: EXPERIMENTAL): The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.~Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).